Erlotinib

• Non-Small Cell Lung Cancer (NSCLC)
• Pancreatic Cancer
• EGFR-Mutated Lung Cancer
• Targeted Cancer Therapy

Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat selected non-small cell lung cancer and locally advanced or metastatic pancreatic cancer. Marketed as Tarceva, it was one of the first targeted therapies to translate molecular tumor profiling into a daily pill. While oncology specialists direct treatment, internal medicine physicians frequently co-manage patients on erlotinib for hypertension, diabetes, dermatologic side effects, and the broader medical issues that arise during cancer therapy. Understanding how erlotinib works, what side effects to expect, and which lab values matter helps patients participate confidently in their own care.

Mechanism of Action

Erlotinib reversibly blocks the intracellular tyrosine kinase domain of EGFR, also called HER1 or ErbB1, by competing with ATP at the catalytic cleft. EGFR is a transmembrane receptor that, when bound by ligands such as EGF or transforming growth factor alpha, dimerizes and autophosphorylates, igniting the RAS-RAF-MEK-ERK proliferation cascade and the PI3K-AKT-mTOR survival pathway. In healthy tissue these signals are tightly regulated. In many epithelial cancers, EGFR is overexpressed, amplified, or carries activating mutations — most commonly exon 19 deletions or the L858R substitution in exon 21 — that produce constitutive signaling independent of ligand binding. By preventing EGFR phosphorylation, erlotinib quiets these downstream cascades, halting cell-cycle progression and triggering apoptosis in tumor cells that have become addicted to EGFR signaling.

The response in lung cancer is dramatic when activating mutations are present, with tumor shrinkage in most patients and progression-free survival measured in many months. Tumors lacking these mutations show modest benefit, which is why molecular testing is mandatory before first-line use. Resistance eventually emerges, often through the T790M gatekeeper mutation, prompting a switch to next-generation agents such as osimertinib. The same EGFR signaling that drives malignant proliferation also maintains skin, hair, and nail integrity — explaining why the acneiform rash, paronychia, and dry skin that develop on therapy are pharmacodynamic markers rather than allergies. Comprehensive label information is available through DailyMed.

Clinical Use

FDA-approved indications include first-line metastatic non-small cell lung cancer with EGFR exon 19 deletion or L858R substitution, maintenance therapy after platinum doublet chemotherapy in patients without progression, and combination therapy with gemcitabine for locally advanced or metastatic pancreatic cancer. EGFR mutation testing on tumor tissue or circulating tumor DNA is required before first-line lung cancer use; treating an EGFR-wild-type tumor with erlotinib offers little benefit and exposes the patient to toxicity unnecessarily. Among patients with sensitizing mutations, response rates approach 70 percent and median progression-free survival ranges from 9 to 13 months.

Newer third-generation EGFR inhibitors such as osimertinib have largely supplanted erlotinib in the first-line setting because of superior central nervous system penetration, longer median progression-free survival, and activity against the T790M resistance mutation. Erlotinib retains a role for patients whose tumors progress on osimertinib but remain EGFR-driven, for those who cannot tolerate osimertinib, or in combination regimens with bevacizumab or ramucirumab. In pancreatic cancer the absolute benefit added to gemcitabine is small — about two weeks of median survival — and modern regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel are usually preferred. Decisions are individualized at multidisciplinary tumor boards, and the National Cancer Institute maintains current treatment overviews.

How to Take It

Erlotinib is taken as a single tablet once daily on an empty stomach — at least one hour before eating or two hours after a meal. Food, especially fatty food, can double absorption and increase toxicity, so consistent timing matters. Many patients take the dose first thing in the morning with water, then eat breakfast at least an hour later. If a dose is missed and the next dose is more than 12 hours away, take it; otherwise skip it. Never double up.

Proton pump inhibitors such as omeprazole and pantoprazole and H2 blockers reduce erlotinib absorption substantially because the drug requires gastric acidity to dissolve. Whenever possible these agents should be avoided; if needed, antacids can be used four hours after the erlotinib dose. Smoking induces CYP1A2 and lowers erlotinib levels by roughly half, so active smokers may be prescribed a higher dose, with prompt dose reduction upon cessation. Tablets are stored at room temperature.

The characteristic acneiform rash usually appears within the first two weeks on the face, scalp, upper chest, and back. It often correlates with response. Daily moisturizer, broad-spectrum SPF 30 or higher sunscreen, and avoiding harsh soaps help. Topical clindamycin or oral doxycycline for moderate cases reduces severity without compromising efficacy.

Monitoring and Follow-Up

Baseline assessment includes complete blood count, comprehensive metabolic panel with liver enzymes and bilirubin, INR if on warfarin, and pregnancy testing. Liver enzymes are checked every 2 to 4 weeks during the first three months and at least monthly thereafter; rising AST or ALT above three times the upper limit of normal, or bilirubin above twice baseline, prompts dose interruption. Renal function and electrolytes are monitored regularly because renal failure has occurred, particularly with concurrent NSAID use and dehydration. Restaging imaging — usually CT chest, abdomen, and pelvis — is repeated every 6 to 12 weeks to assess tumor response.

New or worsening dyspnea, dry cough, or fever raises concern for interstitial lung disease, an uncommon but potentially fatal complication that requires immediate erlotinib discontinuation, high-resolution CT, and pulmonologist consultation. Patients should report eye pain, vision changes, or persistent eye redness given the risk of corneal ulceration. INR is monitored more frequently in patients on warfarin, which can be unpredictably potentiated.

Special Populations

Elderly patients tolerate erlotinib similarly to younger adults but face higher rates of grade 3 or higher toxicity, particularly diarrhea and dehydration. No renal dose adjustment is needed, but caution and close monitoring are warranted in moderate-to-severe hepatic impairment with starting dose reduction recommended when bilirubin exceeds three times the upper limit of normal. Erlotinib is contraindicated in pregnancy because of teratogenic risk; effective contraception is required during therapy and for one month after the last dose for women, and one week for male partners. Breastfeeding is not recommended. Pediatric safety has not been established, and the drug is not used in children.

When to Contact Your Doctor

Call promptly for new shortness of breath or persistent dry cough, severe diarrhea producing more than four extra stools per day, signs of dehydration such as dizziness or reduced urination, yellowing of skin or eyes, severe abdominal pain, eye pain or vision changes, or a rash that becomes painful, blistering, or infected. Black or bloody stools, vomiting blood, or hematuria require immediate evaluation. Any unexplained fever above 100.4°F warrants same-day contact, especially when neutropenia is possible. Discuss any new prescription, over-the-counter medication, or supplement with the oncology team before starting because of the wide drug interaction profile, including significant interactions with strong CYP3A4 inducers and inhibitors.

Beyond pharmacology, patients on erlotinib benefit from a deliberate supportive care plan. Acneiform rash is best managed proactively from day one with twice-daily moisturizer, gentle non-soap cleansers, broad-spectrum sunscreen, and avoidance of harsh exfoliants or alcohol-based products. Many oncology teams prescribe a prophylactic course of doxycycline 100 mg twice daily and topical hydrocortisone for the first six to eight weeks, which substantially reduces rash severity. Diarrhea is managed with loperamide titrated to no more than four loose stools daily, with prompt clinical contact for any escalation. Adequate oral hydration — particularly important in the Florida heat — protects renal function. Patients are asked to bring all over-the-counter medications, vitamins, and herbal supplements to each visit because the drug interaction profile is unusually broad. Smoking cessation support is critical not only because smoking lowers erlotinib levels but also because continued smoking worsens cancer outcomes.

If you are coordinating cancer therapy with primary care needs in St. Petersburg, our team can help manage cardiovascular risk, glycemic control, dermatologic side effects, and preventive care during treatment. Contact us or schedule a visit to set up co-management.